Show simple item record

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial

dc.contributor.authorMackenzie, Isla S.
dc.contributor.authorHawkey, Christopher J.
dc.contributor.authorFord, Ian
dc.contributor.authorGreenlaw, Nicola
dc.contributor.authorPigazzani, Filippo
dc.contributor.authorRogers, Amy
dc.contributor.authorStruthers, Allan D.
dc.contributor.authorBegg, Alan G.
dc.contributor.authorWei, Li
dc.contributor.authorAvery, Anthony J.
dc.contributor.authorTaggar, Jaspal S.
dc.contributor.authorWalker, Andrew
dc.contributor.authorDuce, Suzanne L.
dc.contributor.authorBarr, Rebecca J.
dc.contributor.authorDumbleton, Jennifer S.
dc.contributor.authorRooke, Evelien D.
dc.contributor.authorTownend, Jonathan N.
dc.contributor.authorRitchie, Lewis D.
dc.contributor.authorMacDonald, Thomas M.
dc.contributor.authorAhmed, Husnat
dc.contributor.authorArthur, Peter
dc.contributor.authorAziz, Jane
dc.contributor.authorBarnes, Lawrence
dc.contributor.authorBoyle, Sarah
dc.contributor.authorBrighton, Tom
dc.contributor.authorBrown, Morris
dc.contributor.authorCaulfield, Mark
dc.contributor.authorDawson, Jesse
dc.contributor.authorDenvir, Martin
dc.contributor.authorDoney, Alexander SF
dc.contributor.authorDoshi, Sagar
dc.contributor.authorDryburgh, Moira
dc.contributor.authorEddleston, Michael
dc.contributor.authorFinlayson, Jim
dc.contributor.authorFuat, Ahmet
dc.contributor.authorFurnace, Jacqueline
dc.contributor.authorGrieve, JW Kerr
dc.contributor.authorGuthrie, Greg
dc.contributor.authorHam, Sharon
dc.contributor.authorIsaard, Emma
dc.contributor.authorJennings, Claudine
dc.contributor.authorJohnson, Richard
dc.contributor.authorKerr, Claire
dc.contributor.authorKhan, Sohail
dc.contributor.authorKrishnan, Kailash
dc.contributor.authorLong, Susan
dc.contributor.authorMackintosh, Anne
dc.contributor.authorMacleod, Mary Joan
dc.contributor.authorMcCormack, Terry
dc.contributor.authorWeir, Christopher
dc.contributor.authorALL-HEART Study Group
dc.date.accessioned2022-10-19T07:20:01Z
dc.date.available2022-10-19T07:20:01Z
dc.date.issued2022-10-08
dc.identifier.citationMackenzie , I S , Hawkey , C J , Ford , I , Greenlaw , N , Pigazzani , F , Rogers , A , Struthers , A D , Begg , A G , Wei , L , Avery , A J , Taggar , J S , Walker , A , Duce , S L , Barr , R J , Dumbleton , J S , Rooke , E D , Townend , J N , Ritchie , L D , MacDonald , T M , Ahmed , H , Arthur , P , Aziz , J , Barnes , L , Boyle , S , Brighton , T , Brown , M , Caulfield , M , Dawson , J , Denvir , M , Doney , A SF , Doshi , S , Dryburgh , M , Eddleston , M , Finlayson , J , Fuat , A , Furnace , J , Grieve , JW K , Guthrie , G , Ham , S , Isaard , E , Jennings , C , Johnson , R , Kerr , C , Khan , S , Krishnan , K , Long , S , Mackintosh , A , Macleod , M J , McCormack , T , Weir , C & ALL-HEART Study Group 2022 , ' Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial ' , The Lancet , vol. 400 , no. 10359 , pp. 1195-1205 . https://doi.org/10.1016/S0140-6736(22)01657-9en
dc.identifier.issn0140-6736
dc.identifier.otherPURE: 220058970
dc.identifier.otherPURE UUID: e68e1b73-7af6-4c9c-9e2e-a17a7112c78a
dc.identifier.otherScopus: 85139342056
dc.identifier.otherPubMed: 36216006
dc.identifier.otherORCID: /0000-0003-2115-8184/work/121059598
dc.identifier.urihttps://hdl.handle.net/2164/19397
dc.descriptionFunding Information: ISM reports research grants from Menarini, EMA, Sanofi, Health Data Research UK, the British Heart Foundation, and Innovative Medicines Initiative; institutional consultancy income from AstraZeneca outside the submitted work; and personal income from AstraZeneca and Amgen outside the submitted work. TMM reports grants from Menarini/Ipsen/Teijin and Merck Sharp & Dohme outside the submitted work, and personal income for consultancy from Novartis and AstraZeneca outside the submitted work, and is a trustee of the Scottish Heart Arterial Risk Prevention Society. AGB reports personal income from Novartis, Mylan, AstraZeneca, Bayer, Daiichi-Sankyo, Boehringer, Pfizer, Galderma, Zambon, and Novo-Nordisk outside the submitted work. ADS and the University of Dundee hold a European patent for the use of xanthine oxidase inhibitors in treating chest pain in angina pectoris. AW declares personal income for consultancy from AbbVie, Akcea, Albireo, Alexion, Allergan, Amarin, Apsara, Arena, Astellas, AstraZeneca, Autolus, Bayer, Biocryst, Biogen, Biomarin, Bristol Myers Squibb, Boehringer Ingelheim, Calico, Celgene, Chiesi, Daiichi Sankyo, Diurnal, Elsai, Eli Lilly, Ferring, Galapagos, Gedeon Richter, Gilead, GlaxoSmithKline, GW Pharma, Idorsia, Incyte, Intercept, Ionis, Ipsen, Janssen, Jazz, Jcyte, Kite Gilead, LEK, Leo Pharma, Les Laboratoires Servier, Lundbeck, Merck (Merck Sharp & Dohme), Merck-Serono, Mitenyi, Mundibiopharma, Mustang Bio, Mylan, Myovant, Norgine, Novartis, Novo Nordisk, Orchard, Paion, Pfizer, Pierre Fabre, PTC, RegenXBio, Rhythm, Sanofi, Santen, Sarepta, SeaGen, Shionogi, Sigmatec, SOBI, Takeda, Tanaya, UCB, and Vertex outside the submitted work. JST declares research funding from the UK National Institute for Health and Care Research (NIHR) and NHS England outside the submitted work and membership of a UK National Institute for Health and Care Excellence guideline committee on management of atrial fibrillation. All other authors declare no competing interests. Funding Information: This study was funded by the NIHR Health Technology Assessment programme (HTA 11/36/41 to ISM, IF, CJH, LW, ADS, AGB, AJA, AW, JST, and TMM). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The study was supported by the Scottish Primary Care Research Network, Support for Science Scotland (Grampian, Highlands, Tayside, Fife, Forth Valley, Greater Glasgow and Clyde, Lothian, Ayrshire and Arran, Dumfries and Galloway, and Lanarkshire), and the NIHR Local Clinical Research Networks (East Midlands, West Midlands, Eastern, North Thames, Yorkshire and Humber, North East and North Cumbria, North West Coast, Kent, Surrey and Sussex, and South West Peninsula), which assisted with recruitment and other study activities. We thank Public Health Scotland and NHS Digital for providing data linkage. We thank all the participants, physicians, nurses, and other staff who participated in the ALL-HEART study. Funding Information: This study was funded by the NIHR Health Technology Assessment programme (HTA 11/36/41 to ISM, IF, CJH, LW, ADS, AGB, AJA, AW, JST, and TMM). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care. The study was supported by the Scottish Primary Care Research Network, Support for Science Scotland (Grampian, Highlands, Tayside, Fife, Forth Valley, Greater Glasgow and Clyde, Lothian, Ayrshire and Arran, Dumfries and Galloway, and Lanarkshire), and the NIHR Local Clinical Research Networks (East Midlands, West Midlands, Eastern, North Thames, Yorkshire and Humber, North East and North Cumbria, North West Coast, Kent, Surrey and Sussex, and South West Peninsula), which assisted with recruitment and other study activities. We thank Public Health Scotland and NHS Digital for providing data linkage. We thank all the participants, physicians, nurses, and other staff who participated in the ALL-HEART study. Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseen
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.rightshttps://creativecommons.org/licenses/by/4.0/en
dc.subjectR Medicineen
dc.subjectMedicine(all)en
dc.subject.lccRen
dc.titleAllopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trialen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Biological Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Centre for Health Data Scienceen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciences - Cardiovascular Groupen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Registryen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1016/S0140-6736(22)01657-9
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85139342056&partnerID=8YFLogxKen
dc.identifier.vol400en
dc.identifier.iss10359en


Files in this item

Thumbnail
Name:
Mackenzie_etal_lancet_Allopuri ...
Size:
745.8Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record